Corneal neovascularization is the abnormal growth of blood vessels into the cornea, a tissue that is normally completely transparent and free of blood vessels. When new vessels invade, they bring along blood cells and plasma proteins that scatter light, cloud the cornea, and degrade vision. A large retrospective study at a major Italian eye center found that roughly one in ten corneal patients seen over a 14-year span had some degree of corneal neovascularization, and the condition was linked to measurable losses in both visual acuity and contrast sensitivity.1PubMed Central. Epidemiology of Corneal Neovascularization and Its Impact on Visual Acuity and Sensitivity: A 14-Year Retrospective Study The process sounds simple, but the biology behind why it happens and how clinicians try to stop it is far more layered than “blood vessels where they shouldn’t be.”
Why the Cornea Is Normally Blood-Vessel-Free
The cornea is one of the few tissues in the body that actively suppresses blood vessel growth. It sits in a state researchers call “angiogenic privilege,” meaning it doesn’t just lack vessels passively; it manufactures molecules whose entire job is to keep vessels out. The most important of these is a soluble form of VEGF receptor-1, commonly called sflt-1. This molecule acts as a decoy trap: it binds vascular endothelial growth factor (VEGF-A), the protein that normally signals blood vessels to sprout, and neutralizes it before vessels can form. When researchers knocked out sflt-1 in mice using gene disruption or RNA interference, the corneas spontaneously grew blood vessels.2PubMed Central. Corneal avascularity is due to soluble VEGF receptor-1
A parallel system keeps lymphatic vessels out as well. The cornea produces a truncated form of VEGF receptor-3 (sVEGFR-3) that traps VEGF-C, the growth factor that drives lymphatic vessel formation. When sVEGFR-3 was knocked down in mouse corneas, both lymphatic and blood vessels invaded. Overexpressing it had the opposite effect, blocking both types of vessel growth in an injury model.3PubMed Central. Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity So the cornea runs two separate anti-vessel defense systems simultaneously, one targeting blood vessels and one targeting lymphatics.
There is also a physical barrier. The limbus, the ring of tissue where the cornea meets the white of the eye, acts as a border separating the avascular corneal surface from the heavily vascularized conjunctiva.4PubMed Central. Concise review: limbal stem cell deficiency, dysfunction, and distress Limbal stem cells continuously regenerate the corneal surface, and as long as they remain healthy, conjunctival tissue and its blood vessels stay on their side of the border. Damage to this limbal barrier is one of the most common starting points for corneal neovascularization.
What Triggers Vessel Growth
Corneal neovascularization isn’t one disease; it is a response to many different insults. The common thread is that something overwhelms the cornea’s anti-vessel defenses and tips the balance toward pro-angiogenic signaling. The major triggers include:
- Contact lens wear: Extended or overnight contact lens use restricts oxygen delivery to the cornea. In a mouse model of closed-eye contact lens wear, hypoxia activated HIF-1α (a transcription factor that responds to low oxygen), which in turn ramped up VEGF expression and drove time-dependent vessel growth.5PubMed Central. Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1α in a mouse model of closed eye contact lens wear
- Chemical burns: Alkali injuries are particularly destructive because the alkaline solution penetrates deep into the cornea quickly, killing cells and triggering an intense inflammatory and hypoxic cascade that promotes new vessel invasion.6Ophthalmology Science. Supersaturated Oxygen Emulsion Mitigates Hypoxia-Driven Corneal Neovascularization after Alkali Burn
- Infections: Herpes simplex stromal keratitis is one of the most studied infectious causes. The chronic inflammation that herpes provokes in the corneal stroma attracts immune cells that release pro-angiogenic signals.
- Previous corneal transplants: A graft can trigger neovascularization, which in turn raises the risk of rejection for that graft or any future transplant.
- Limbal stem cell failure: When the limbal stem cell population is depleted or dysfunctional, the conjunctival epithelium creeps across the border, bringing blood vessels with it.
The common molecular link in all of these scenarios is a shift toward excess VEGF and related growth factors overwhelming the natural VEGF traps the cornea depends on.
What Happens at the Molecular Level
VEGF-A is the central villain, but it doesn’t act alone. Matrix metalloproteinases (MMPs), a family of enzymes that break down the tissue scaffolding around cells, play a significant amplifying role. In a rat cornea model, pellets containing active MMP-2 and MMP-9 triggered local VEGF production in the corneal epithelium within 24 hours of implantation, even without any external VEGF being supplied.7The American Journal of Pathology. Cross-Talk between Vascular Endothelial Growth Factor and Matrix Metalloproteinases in the Induction of Neovascularization in Vivo A separate study found that MMP-14 is upregulated after corneal injuries and specifically drives the VEGF-C/VEGFR-3 signaling axis that promotes lymphatic vessel growth.8PubMed Central. Matrix metalloproteinase 14 participates in corneal lymphangiogenesis through the VEGF-C/VEGFR-3 signaling pathway In other words, the tissue-remodeling enzymes released during injury or infection don’t just clear debris; they actively recruit new vessels by coaxing the surrounding cells into producing more growth factors.
Immune cells, particularly macrophages, add another layer. After injury, macrophages infiltrate the cornea and become major local producers of VEGF. Even the process of clearing small hemorrhages from fragile new vessels draws more macrophages, which secrete more VEGF, creating a self-reinforcing loop.9PubMed Central. Lipid Keratopathy: A Review of Pathophysiology, Differential Diagnosis, and Management The newly formed vessels themselves are structurally sloppy: they lack normal pericyte coverage, have fewer basement membrane layers, and are missing tight junctions between their endothelial cells. This makes them leaky, which is where the downstream vision problems begin.
How Neovascularization Damages Vision
The vessels alone scatter incoming light, but the real damage often comes from what they leak. Because the new vessels are abnormally permeable, lipids and cholesterol from the blood seep into the corneal stroma. Over time this can produce lipid keratopathy, visible as white or yellowish fatty deposits in the cornea.10PubMed Central. Lipid Keratopathy: A Review of Pathophysiology, Differential Diagnosis, and Management These deposits are dense and opaque, and they persist even if the vessels are later closed off, making early treatment important.
Neovascularization also wrecks the cornea’s special immune status. A healthy, vessel-free cornea is an immunologically privileged site, meaning it can tolerate foreign tissue better than most parts of the body. This is the reason corneal transplants historically had high success rates even without tissue matching. When blood and lymphatic vessels invade, they provide highways for immune cells to reach the cornea and for corneal antigens to travel back to lymph nodes. The result is a dramatic increase in graft rejection risk.11PubMed Central. Corneal Allograft Rejection: Immunopathogenesis to Therapeutics For patients who need corneal transplants, pre-existing neovascularization is one of the strongest predictors that the graft will fail.
Diagnosing and Measuring Severity
Basic corneal neovascularization is visible during a standard slit-lamp exam. The challenge is quantifying it precisely, especially when the vessels extend deep into the stroma. Anterior segment optical coherence tomography angiography (AS-OCTA) has emerged as a noninvasive way to image corneal vessels in three dimensions. In a pilot study, AS-OCTA vessel density and vessel branch area correlated with the severity of corneal vascularization as measured by indocyanine green angiography, and vessel density followed an inverse relationship with vessel leakage time, meaning denser vessel networks tended to be leakier.12PubMed Central. A pilot study investigating anterior segment optical coherence tomography angiography as a non-invasive tool in evaluating corneal vascularisation
Researchers have also proposed using AS-OCTA to measure novel parameters like vessel depth within the stroma, the three-dimensional volume of the neovascular tissue, and how far the vessels have penetrated toward the visual axis. These measurements can be performed without injecting any dye, which is a significant advantage over older angiographic techniques that required intravenous fluorescein or indocyanine green.13PubMed Central. Novel Parameters to Assess the Severity of Corneal Neovascularization Using Anterior Segment Optical Coherence Tomography Angiography For clinicians, these quantitative tools make it much easier to track whether a treatment is actually shrinking the vascular network or just stabilizing it.
Anti-VEGF Therapy
Because VEGF-A is the dominant driver, anti-VEGF drugs, particularly bevacizumab (the same antibody used in cancer treatment and retinal disease), have become a go-to option. In a prospective study, subconjunctival bevacizumab injection led to vessel recession in all treated eyes within one week. The neovascular area shrank from about 11% of the corneal surface before injection to about 8% after, a mean reduction of roughly 25%. No local or systemic side effects were observed.14PubMed. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study However, vessel regression peaked at one month and then the vessels started creeping back, which is a recurring frustration with anti-VEGF monotherapy.
In a high-risk corneal transplant setting, combining topical and subconjunctival bevacizumab over a year produced more durable results. Bevacizumab-treated eyes showed an 84% reduction in vessel area over 52 weeks compared with about 62% in the control group, and the invasion area shrank by about 76% versus 47%.15Ophthalmology Science. Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation The takeaway from the broader evidence is that anti-VEGF drugs can push vessels back, but sustained or repeated treatment tends to be necessary, and in many patients the response is partial rather than complete.
Immunosuppressive Alternatives
The therapeutic landscape is broader than anti-VEGF alone. Immunosuppressive drugs can attack the problem from a different angle by dampening the inflammatory signals that feed vessel growth. Tacrolimus, a calcineurin inhibitor widely used after organ transplants, has shown promise. In a randomized trial of stromal herpetic keratitis, topical tacrolimus reduced corneal neovascularization, edema, and haziness to a greater degree than the control treatment, and the anti-angiogenic effect has been compared favorably with bevacizumab.16PubMed Central. Topical Tacrolimus as an adjunct to Conventional Therapy for Stromal Herpetic Keratitis: a Randomized Clinical Trial
A multicenter pilot trial tested topical 0.1% tacrolimus head-to-head against prednisolone acetate (a standard steroid) in patients with corneal neovascularization. Both drugs reduced vessels during the first four weeks, but tacrolimus sustained the reduction out to eight weeks while the steroid group did not maintain the same level of improvement.17Advances in Ophthalmology Practice and Research. Clinical Efficacy of Topical 0.1% Tacrolimus in Patients with Corneal Neovascularization: A Prospective, Multicenter, Randomized Controlled Pilot Trial Cyclosporine and rapamycin have also been explored in this space.18PubMed Central. Available Therapeutic Options for Corneal Neovascularization: A Review These immunosuppressive options are particularly appealing for patients with inflammation-driven neovascularization, where simply blocking VEGF without addressing the immune response may not be enough.
Procedural Treatments and the Rebound Problem
For mature, established vessels that are no longer responsive to drug therapy, physical destruction is sometimes necessary. Fine needle diathermy (FND) uses a needle tip delivering low-voltage cautery to obliterate vessels within the stroma. It is inexpensive and fairly effective, though complications like intrastromal bleeding and crystalline deposits can occur, and it sometimes needs to be repeated.19PubMed. Fine needle diathermy occlusion of corneal vessels Photodynamic therapy with verteporfin, a light-activated drug that damages vessel walls, achieved complete vascular occlusion in half the treated eyes at one year and partial regression in another 28%, with two patients going on to successful corneal transplants without revascularization.20PubMed. Photodynamic therapy with verteporfin for corneal neovascularization
A significant problem with cautery-based approaches is rebound angiogenesis. FND effectively destroys vessels at early time points, but the tissue destruction it causes triggers a secondary wave of inflammation. Macrophages flood in, pro-angiogenic growth factors spike, and vessels regrow. One study found that FND as monotherapy led to significant upregulation of VEGF-A, VEGF-C, and VEGF-D in the aftermath, along with macrophage infiltration that fueled secondary vessel growth. Adding anti-VEGF therapy after FND prevented this rebound.21PubMed Central. Supplemental Anti Vegf A-Therapy Prevents Rebound Neovascularisation After Fine Needle Diathermy Treatment to Regress Pathological Corneal (LYMPH)Angiogenesis The lesson is that destroying vessels without addressing the molecular environment that grew them in the first place often just restarts the cycle.
Gene Therapy on the Horizon
One of the more compelling research directions aims to restore the cornea’s natural anti-vessel defenses permanently rather than relying on repeated drug injections. Using an adeno-associated viral vector (AAV) to deliver the gene for sflt-1, the same natural VEGF trap the cornea normally produces, researchers achieved long-lasting protection in mouse corneas. A single injection into the corneal stroma prevented blood vessel growth when challenged with a strong angiogenic stimulus at 3, 28, and even 210 days after the gene was delivered. A combined approach delivering both sflt-1 and sflt-4 (which targets lymphatic vessel growth) showed signs of synergistic protection.22PubMed. Stromal Gene Therapy Mediates Prolonged Protection Against Corneal Neovascularization Induced by an Aggressive Angiogenic Insult
This approach is conceptually elegant because it mirrors what healthy corneas already do. Instead of repeatedly injecting anti-VEGF drugs from outside, the idea is to make corneal cells continuously produce the endogenous VEGF trap themselves. The work is still in animal models, and the jump from mouse corneas to human clinical trials involves clearing safety and durability hurdles. But the results so far are encouraging, particularly the finding that protection held at seven months after a single injection.
Limbal Stem Cell Transplantation
When neovascularization results from limbal stem cell deficiency, whether from chemical burns, repeated surgeries, or genetic conditions, restoring the limbal barrier itself can be necessary. Without a functioning population of limbal stem cells, the corneal surface cannot regenerate properly, and conjunctival tissue carrying blood vessels invades. In partial limbal stem cell deficiency, surgically removing the invading conjunctival tissue and applying an amniotic membrane graft can sometimes be enough to restore a healthy surface. In more complete deficiency, limbal stem cell transplantation from a donor eye or from the patient’s own healthy eye (if only one eye is affected) is the standard approach.23PubMed Central. Limbal stem cell transplantation: current perspectives This is not a treatment for the vessels themselves so much as a repair of the barrier system that keeps vessels out.
An Unusual Case Worth Knowing About
Corneal neovascularization occasionally turns up in unexpected clinical contexts. One published case involved a patient with obstructive sleep apnea who used a continuous positive airway pressure (CPAP) machine. Slit-lamp examination revealed neovascularization and lipid exudation in the lower third of the cornea. The hypothesis was that chronic air leak from the mask created a cycle of corneal exposure, drying, and low-grade hypoxia that eventually tipped the cornea’s angiogenic balance.24Case Reports in Ophthalmology. Corneal Neovascularization with Associated Lipid Keratopathy in a Patient with Obstructive Sleep Apnea-Hypopnea Syndrome Using a Continuous Positive Airway Pressure Machine Cases like this underscore that the condition isn’t limited to classic triggers like contact lenses and infections; anything that chronically stresses the corneal surface can, over time, breach its anti-vessel defenses.
How Corneal Structure Varies Across Species
The cornea’s architecture is not the same in every animal, and these differences have implications for how angiogenic privilege works. In fish, the corneal stroma is built from orthogonally arranged collagen sheets that run from edge to edge, resembling plywood. Amphibians and reptiles have broader collagen lamellae that begin to branch and connect across layers. Birds take this branching to an extreme, with a “chicken wire” pattern that produces a particularly stiff and well-integrated stroma. Mammals, including humans, diverged from this pattern, developing a more random lamellar arrangement with branching concentrated in the front of the stroma, where mechanical stiffness is highest.25PubMed. Evolution of the vertebrate corneal stroma The progressive increase in structural complexity from fish to birds and mammals likely interacts with the molecular anti-angiogenic defenses to maintain corneal transparency. Researchers studying corneal neovascularization in animal models need to account for these structural differences, because a treatment that works well in a loose fish-like stroma may behave quite differently in the dense, randomly woven stroma of a mammalian cornea.